Clinical Report: Evaluating Progression-Free Survival with PARP Inhibitors in Ovarian Cancer

Overview

This exploratory study investigates the relationship between baseline physiological vulnerability and progression-free survival (PFS) in ovarian cancer patients treated with PARP inhibitors.

Background

Ovarian cancer is a leading cause of cancer-related mortality among women, with a significant proportion diagnosed at advanced stages. PARP inhibitors have emerged as a standard treatment, particularly for patients with BRCA mutations. However, variability in treatment response among patients with similar molecular profiles necessitates exploration of additional factors, such as physiological vulnerability.

Data Highlights

This study analyzed data from 604 ovarian cancer patients, utilizing a 0–3 organ vulnerability score (OVS) based on pre-treatment laboratory indicators. Key findings include:

Key Findings

• The association between BRCA mutation status and PFS was consistent with prior evidence (HR = 0.685, P = 0.028).
• A significant treatment-by-OVS interaction was observed (interaction HR = 0.488, P = 0.006).
• In patients with low vulnerability (OVS 0–1), olaparib showed a modest PFS advantage over niraparib (HR = 0.744, P = 0.030).
• In high vulnerability patients (OVS 2–3), olaparib's relative benefit was more pronounced (HR = 0.363, P < 0.001).
• Individual-level variation in treatment response was noted, with some patients favoring niraparib.
• The findings were qualitatively reproduced in an external cohort of 58 patients.

Clinical Implications

Clinicians should consider physiological factors alongside molecular markers when evaluating treatment options for ovarian cancer patients.

Conclusion

The study indicates that baseline physiological vulnerability may be associated with the effectiveness of PARP inhibitors in ovarian cancer.

Related Resources & Content

1. The ASCO Post, PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease, 2021 -- KEY POINTS Related Articles
2. The ASCO Post, Advanced Epithelial Ovarian Cancer: First-Line PARP Inhibitor Maintenance Therapy and Survival, 2025
3. The ASCO Post, Expert Point of View: Novel Agents Prolong Disease-free Survival in Ovarian Cancer, 2011
4. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer, 2026
5. The ASCO Post — SIDEBAR: Future of PARP Inhibitors in Ovarian Cancer Hangs in Balance
6. NCCN Ovarian Cancer Guidelines, 2026
7. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer - PMC
8. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | New England Journal of Medicine
9. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | New England Journal of Medicine
10. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial - PMC
11. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) | Journal of Clinical Oncology
12. Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial - PubMed
13. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial - PMC
14. DailyMed - LYNPARZA- olaparib tablet, film coated
15. DailyMed - RUBRACA- rucaparib tablet, film coated